Business Wire

TAKEDA-PHARMACEUTICAL

11.6.2020 08:02:10 CEST | Business Wire | Press release

Share
Takeda Selects Two New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Support Strong Health Systems and Access to Healthcare in Developing Countries

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK ) (“Takeda”) today announced the addition of two partners to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare systems and improve access to healthcare for all in developing countries. As part of an annual decision-making process, Takeda employees worldwide have voted to add the Access to Health Fund and Bridges to Development as new partners for the Global CSR Program , which now supports 16 programs in more than 60 countries.

Takeda’s commitments to these new partner organizations in FY2020 include:

  • JPY 1.1 billion (USD 10.1 million*) to Access to Health Fund to help build and improve community health centers and empower health staff from ethnic health organizations and ethnic community-based health organizations (EHOs/ECBHOs) in Myanmar’s Shan State to deliver quality health services, particularly for mothers and children, over the next 5 years.
  • JPY 681 million (USD 6.3 million* ) to Bridges to Development to eliminate or control 5 neglected tropical diseases in Papua New Guinea and Vanuatu including lymphatic filariasis, yaws, leprosy, trachoma, and soil-transmitted helminthiases. The 3-year project will improve health worker capacity, access to care and treatment.

“We welcome and very much value the interest that Takeda and its employees have shown in contributing to improving the health of vulnerable populations in conflict-affected and hard-to-reach areas in Shan State in Myanmar,” said Oren Ginzburg, Access to Health Fund Director.

“The Bridges team is thrilled to embark on this important work in service of communities and populations that have been frequently left behind,” said Julie Jacobson, Managing Partner & Co-Founder of Bridges to Development. “In this project, working with countries, we aim to achieve lasting health benefits through the elimination and control of several neglected tropical diseases in one innovative approach. We are thankful to Takeda employees who helped make this possible with their support.”

This year represents the 5th anniversary of Takeda’s Global CSR Program, which empowers employees in Takeda’s 80 countries of operation to be the decisionmakers for which innovative, high-impact activities receive the Company’s support. The Program, rooted in the company’s values , actively partners with world-class organizations and nongovernmental organizations (NGOs) with proven track records of addressing global health problems in effective, enduring ways to prevent disease, train health workers, strengthen supply chains, and improve access to quality diagnosis and treatment for patients worldwide.

“Since its launch in 2016, Takeda’s Global CSR Program has focused on initiatives that strengthen health systems and increase access across the patient journey in low- and middle-income countries. We’re expecting to reach at least 17 million beneficiaries through 2025 globally” said Takako Ohyabu, Chief Global Corporate Affairs Officer. “We are proud to partner with the Access to Health Fund and Bridges to Development as we strive to increase health worker capacity and preventive care for patients everywhere, ensure reliable access to essential equipment and supplies, and empower communities with knowledge, services, and access to care."

In less than five years, Takeda’s Global CSR Program partners have delivered transformational impact that serves communities worldwide today and will continue to contribute to better health outcomes and stronger health systems for years to come, including:

  • JOICFP, Plan International, and UNICEF reached nearly 700,000 pregnant women and mothers, newborns, children, and adolescents, with quality health care, services, and education in sub-Saharan Africa and the Middle East.
  • JOICFP, Plan International, Seed Global Health, and UNICEF in Africa and the Middle East, with World Vision in South Asia, have collectively trained approximately 6,000 health workers in 15 countries, including qualified nurses, midwives, and physician trainees, as well as community health workers and nutrition volunteers.
  • Millions of children have been immunized against measles, and the capacity of trainings offered by academic and clinical institutions in sub-Saharan Africa has been expanded exponentially.

In line with Takeda’s core values and longstanding support for strong health systems and access to healthcare for all, Takeda recently announced contributions to the global COVID-19 response through three United Nations-led organizations to strengthen health systems, improve access to care and supplies, and address food insecurity.

Takeda also forges farsighted public-private philanthropic partnerships with game-changing multilateral and academic institutions worldwide, such as with The Global Fund to Fight AIDS, Tuberculosis and Malaria , and the London School of Hygiene & Tropical Medicine .

* Financial information relating to the donations has been converted from JPY to USD using the ¥108.87:$1 as of June 3, 2020. For the avoidance of doubt, the amounts payable as part of the donations are denominated in JPY.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 22:08:00 CET | Press release

Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl

Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 22:05:00 CET | Press release

Key Takeaways: Enables enterprises to replace high-cost and recurring SaaS licensing fees with high-performance and cost-efficient NVIDIA-based solutions Offerings are derived from Grid Dynamics’ proven customer solutions and leverage NVIDIA’s technology stack Commercially deployed, with additional customers expressing interest NVIDIA and Grid Dynamics jointly presented these solutions at the National Retail Federation (NRF) conference in January 2026 Learn more in NVIDIA’s published blog Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven suc

Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 22:01:00 CET | Press release

Fourth Quarter and Full Year 2025 Financial Highlights Include:Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior yearAdjusted Calculated Billings, full year 2025, up 4.2% from the prior yearAdjusted Annualized Recurring Revenue (ARR) up 3.1% from the prior year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind

Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 18:25:00 CET | Press release

Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 18:00:00 CET | Press release

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeksVedolizumab’s safety profile was generally consistent with its known safety profile in adultsResults were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye